Afala tablets blister pack No. 100




Afala tablets are indicated for:
for the treatment of benign prostatic hyperplasia of stages I and II; as part of complex therapy for acute and chronic prostatitis - as an anti-inflammatory and analgesic; for dysuric disorders (frequent urge to urinate, including nocturnal, difficulty urinating, pain or discomfort in the perineum), including those accompanying benign prostatic hyperplasia of stages I and II; for acute and chronic prostatitis.Composition
Active ingredients: 1 tablet contains affinity purified antibodies to prostate-specific antigen: a mixture of homeopathic dilutions C12, C30 and C200 - 0.003 g (3 mg);
Excipients: lactose, microcrystalline cellulose, magnesium stearate.
Contraindication
Increased individual sensitivity to the components of the drug.
Method of application
Inside. 2 tablets per dose (keep in mouth until completely dissolved - not during meals). Take the drug twice a day, in the evening and in the morning (before and after sleep). The recommended duration of taking the drug is 16 weeks.
With severe pain syndrome and dysuric disorders in the first 2-3 weeks of therapy, taking the drug up to 4 times a day is indicated.
If necessary, on the recommendation of a doctor, a repeated course of treatment may be carried out after 1 - 4 months.
Application features
Pregnancy
Not used by women.
Children
Contraindicated.
Drivers
No effect.
Overdose
In case of accidental overdose, dyspeptic symptoms caused by the excipients included in the dosage form are possible.
Side effects
When using the drug according to the indicated indications and in the indicated doses, no side effects were detected.
Interaction
No cases of incompatibility with other drugs have been registered to date.
Storage conditions
Store at a temperature not exceeding 25ºС, out of the reach of children.
Shelf life - 3 years.
There are no reviews for this product.
There are no reviews for this product, be the first to leave your review.
No questions about this product, be the first and ask your question.